Levodopa is the most effective treatment for Parkinson's disease (PD), but prolonged use in patients is associated with motor complications including motor and nonmotor response fluctuations and a range of levodopa-induced dyskinesias [1] [2] [3] [4] . Motor complications are thought to be caused by fluctuating levodopa blood levels due to irregular gastric emptying and intestinal levodopa absorption (delayed 'On' and no 'On'), the short half-life of levodopa and resulting maladaptive neuroplasticity [5, 6] . Motor and nonmotor complications have been shown to negatively impact quality of life (QoL) in patients with advanced PD.
Levodopa-carbidopa intestinal gel (LCIG, designated in the USA as carbidopa-levodopa enteral suspension [CLES] ; Duopa R /Duodopa R , AbbVie Inc., IL, USA) is delivered continuously via percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG-J) and is a long-term treatment option for motor fluctuations in patients with advanced PD who are refractory to oral medication. LCIG has been shown to reduce motor and nonmotor complications and improve QoL in patients with advanced PD [7] [8] [9] [10] .
The GLORIA registry [11, 12] evaluated the long-term efficacy and safety of LCIG in routine care of patients with advanced PD. This post hoc analysis of the GLORIA registry evaluated the long-term effect of LCIG on dyskinesia burden (dyskinesia duration and severity) in subgroups of patients.
Methods

Study design & treatment
GLORIA is a multinational observational registry designed to collect efficacy and safety data of routine clinical care use of LCIG over 24 months. This registry has been described previously in more detail [11, 12] . GLORIA was conducted according to Good Clinical Practice Guidelines and Institutional Review Board requirements, as applicable.
Patients were individually titrated to LCIG via nasojejunal (NJ) tube. After PEG-J placement, patients were treated for up to 24 months with LCIG. Concomitant PD medications were allowed at the discretion of the investigator.
Patients
Patients were enrolled in the registry according to the European Summary of Product Characteristics (having advanced levodopa-responsive PD with persistent severe motor fluctuations with or without troublesome dyskinesia) and national reimbursement criteria, where applicable. Patients were either LCIG naive or had received LCIG for a maximum of 12 months before enrollment. Observations were prospective for LCIG-naive patients and were partially retrospective and prospective for patients with previous LCIG experience.
Assessments
Efficacy assessment
Efficacy outcomes described in this analysis include the mean change from baseline to study visit as evaluated by the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV (complications of therapy including dyskinesia); items 32 and 39 were modified using the rating instructions for the corresponding parts 4.3 and 4.1 of the Movement Disorder Society (MDS)-UPDRS to allow for collection of actual hours of 'Off ' time and 'On' time with dyskinesia as reported by the patient for the week prior to the clinical visit. UPDRS Part II (activities of daily living) and Part III (motor examination) were also assessed (in the 'On' state). Patient QoL was assessed via the 8-item Parkinson's Disease Questionnaire (PDQ-8). Efficacy was assessed at baseline before the initiation of LCIG via NJ tube; at discharge from hospital following PEG-J placement (day 1); and at 6, 12, 18 and 24 months after PEG-J placement.
Safety assessment
Adverse drug reactions (ADRs) included all adverse events that had a reasonable possibility of being related to the treatment drug or device (as determined by the investigator). ADRs were recorded for the duration of the registry study and for 28 days after the patient's last visit.
Statistical analysis
For this posthoc analysis, patients were allocated into two subgroups based on baseline hours/day of dyskinesia defined as low (<4 h/day) and high (≥4 h/day). Patients without baseline dyskinesia assessment were excluded from the analysis. Statistical significance in the change from baseline to each time point for each efficacy measure was evaluated using a paired t-test.
Results
Patients
Out of 375 patients in the GLORIA registry, there were 118 patients (31%) with <4 h/day of dyskinesia at baseline and 139 patients (37%) with ≥4 h/day dyskinesia at baseline (118 patients [31%] did not have measurements of dyskinesia duration at baseline). Overall, 258 patients (69%) completed the registry; cumulative withdrawals were higher in patients with high versus low baseline dyskinesia (51 [37%] vs 36 [31%] patients). The most prominent reasons for withdrawal were ADRs (n = 46; 12.3%), withdrawal of informed consent (n = 31; 8.3%), patients lost to follow-up (n = 16; 4.3%) and lack of efficacy (n = 11; 2.9%). Demographics were similar across the subgroups LCIG: Levodopa-carbidopa intestinal gel; SD: Standard deviation.
( Table 1 ). Patients with <4 h/day of dyskinesia at baseline had slightly shorter PD duration, a slightly higher total daily levodopa dose, a slightly higher daily 'Off ' time and fewer hours per day of dyskinesia. Activities of daily living, motor symptoms and QoL were similar in both subgroups. During 24 months of treatment, patients on LCIG monotherapy (e.g., no adjunctive therapy during the 16 h of LCIG infusion) had similar increases in levodopa-equivalent doses (LEDs), regardless of baseline dyskinesia ( Table 2) . The LEDs for patients on LCIG polytherapy (LCIG and ≥1 other anti-PD drug) were generally stable over 24 months with LEDs starting and ending at 2191.5 (846.1) mg/day and 2214.5 (840.3) mg/day, respectively, for patients with <4 h/day baseline dyskinesia, and starting and ending at 1787.1 (793.8) mg/day and 1787.6 (769.7) mg/day, respectively, for patients with ≥4 h/day baseline dyskinesia.
Efficacy 'Off''time
Mean 'Off ' time significantly decreased and remained stable for the study duration in both high and low baseline dyskinesia subgroups (p < 0.0001 for both groups) ( Figure 1A) . By month 24, the mean (standard deviation [SD]) 'Off ' time reduced by 3.9 (3.4) h in patients with high baseline dyskinesia and reduced by 4.4 (3.6) h in patients with low baseline dyskinesia (p < 0.0001 for both).
Dyskinesia
In patients with high baseline dyskinesia, the mean (SD) duration of dyskinesia decreased and remained stable through month 24 (reduction of 3.5 [4.6] h; p < 0.0001; Figure 1B ). In patients with low baseline dyskinesia, however, the mean duration of dyskinesia increased and maintained that increase through 24 months of treatment (+1.6 [3.3] h; p < 0.0001).
future science group www.futuremedicine.com Dyskinesia severity (UPDRS item 33) improved significantly over 24 months of treatment in patients with ≥4 h baseline dyskinesia (p < 0.0001 for all time points; Figure 1C ). In patients with low baseline dyskinesia, the severity of dyskinesia numerically improved with statistical significance at month 12 (p < 0.05). Pain associated with dyskinesia (UPDRS item 34) also improved numerically with statistical significance at day 1 (p < 0.05) in patients who had low and high baseline dyskinesia, but was only reduced in patients who had high baseline dyskinesia duration through month 24 (p < 0.0001 for all time points) ( Figure 1D ).
Other motor symptoms
Motor scores (UPDRS Part III) decreased from baseline, regardless of baseline dyskinesia. More specifically, after initiation of LCIG, patients experienced significant (p < 0.0001) reductions from baseline in UPDRS Part III mean (SD) scores of -4.3 (8.7) and -4.5 (7.4) in patients with <4 h/day and ≥4 h/day baseline dyskinesia, respectively. After 24 months, patients with low and high baseline dyskinesia had reductions from baseline in UPDRS Part III mean scores of -1.6 (10.8) and -2.9 (12.8), respectively, although these reductions were not statistically significant.
Activities of daily living & QoL
The ability to perform activities of daily living, as measured by UPDRS Part II, improved in both patient subgroups ( Figure 1E ). Through month 18, patients with high baseline dyskinesia experienced significant (p < 0.05) improvements from baseline; by month 24, scores were still numerically, but not significantly, reduced from baseline in both subgroups.
LCIG treatment led to significant improvements in QoL in both dyskinesia subgroups, although improvements were greater in patients with high baseline dyskinesia ( Figure 1F ). After LCIG initiation, PDQ-8 scores were significantly (p < 0.05 for all) reduced from baseline until month 12 for patients with low baseline dyskinesia and until month 24 (p < 0.01 for all) for patients with high baseline dyskinesia.
Safety
Overall, the proportion of patients experiencing ADRs was similar in both the high and low baseline dyskinesia subgroups (Table 3) . Serious ADRs occurred slightly more frequently in the low versus high baseline dyskinesia duration subgroup (28.2 vs 22.3%, respectively), although fewer patients with low baseline dyskinesia experienced severe ADRs (12.7 vs 16.9%, respectively). The most common ADR leading to LCIG discontinuation that occurred in two patients was device dislocation; all other ADRs leading to discontinuation occurred in one patient each. ADRs leading to LCIG discontinuation were reported by more patients with high baseline dyskinesia than by patients with low baseline dyskinesia. The most commonly reported nondevice-related ADRs (occurring in ≥3% future science group www.futuremedicine.com of patients in either group) were decreased weight, polyneuropathy, Parkinsonism, dyskinesia, psychotic disorder, depression, abdominal pain, hallucination and fall.
Discussion
In this posthoc analysis of the GLORIA study, LCIG-treated patients with advanced PD who had ≥4 h/day of dyskinesia at baseline had significant and sustained reductions in dyskinesia time, severity and associated pain over 24 months of treatment, despite an increase in levodopa-equivalent daily dose. These results align with the concept that changing the pattern of levodopa delivery from pulsatile to continuous is a critical factor in reducing pre-existing levodopa-induced dyskinesias [13] [14] [15] [16] . Previous studies with continuous drug delivery schemes, both of levodopa with LCIG and apomorphine (subcutaneous), have likewise shown reductions in dyskinesia burden despite increases in LED [17] [18] [19] . Imaging data using raclopride positron emission tomography scan have indeed suggested sustained synaptic dopamine release with continuous intrajejunal levodopa infusion [20] . These data expand on previous reports of the effect of LCIG on dyskinesia in patients with advanced PD [18, 19] , with a larger patient population observed over a longer period of time in the current study.
Patients with <4 h/day of dyskinesia at baseline experienced increased duration of dyskinesia over the course of the study, but at the same time there was numerical improvement of dyskinesia severity. Pain associated with dyskinesia and QoL also improved indicating that increased dyskinesia duration was due to nontroublesome involuntary movements.
As expected, LCIG treatment led to a significant decrease in 'Off ' time, regardless of baseline dyskinesia duration. Patients with ≥4 h/day of dyskinesia at baseline experienced significant improvements in QoL over 24 months of LCIG treatment; those with low dyskinesia burden at baseline did so through month 12. ADRs were consistent with the known safety profile of LCIG and were comparable between subgroups.
Although this open-label, noncontrolled registry is limited also by its posthoc nature, it provides a clearer understanding of the impact of continuous administration of levodopa on dyskinesia, which has not been extensively studied. Future prospective studies of the effect of LCIG on dyskinesia in patients with advanced PD are warranted. One such study (NCT02799381) is ongoing and is using the Unified Dyskinesia Rating Scale with the primary outcome being the effect of LCIG on dyskinesia in advanced PD patients. 
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